RDY Ebitda from 2010 to 2024

RDY Stock  USD 14.46  0.14  0.98%   
Dr Reddys EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, Dr Reddys EBITDA regression line of annual values had r-squared of  0.76 and arithmetic mean of  41,547,238,092. View All Fundamentals
 
EBITDA  
First Reported
2001-06-30
Previous Quarter
21.8 B
Current Value
23.9 B
Quarterly Volatility
5.8 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Dr Reddys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dr Reddys' main balance sheet or income statement drivers, such as Interest Expense of 1.8 B, Total Revenue of 293.1 B or Gross Profit of 171.8 B, as well as many indicators such as Price To Sales Ratio of 3.91, Dividend Yield of 0.0061 or PTB Ratio of 3.89. RDY financial statements analysis is a perfect complement when working with Dr Reddys Valuation or Volatility modules.
  
Check out the analysis of Dr Reddys Correlation against competitors.

Latest Dr Reddys' Ebitda Growth Pattern

Below is the plot of the Ebitda of Dr Reddys Laboratories over the last few years. It is Dr Reddys' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dr Reddys' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

RDY Ebitda Regression Statistics

Arithmetic Mean41,547,238,092
Geometric Mean32,321,363,031
Coefficient Of Variation62.47
Mean Deviation19,918,489,526
Median34,386,000,000
Standard Deviation25,954,400,482
Sample Variance673630904.4T
Range90.5B
R-Value0.87
Mean Square Error177347132.9T
R-Squared0.76
Significance0.000026
Slope5,044,558,573
Total Sum of Squares9430832661.1T

RDY Ebitda History

202492.8 B
202388.4 B
202274.4 B
202147.7 B
202045.7 B
201949.5 B
201823.6 B

About Dr Reddys Financial Statements

Dr Reddys investors use historical fundamental indicators, such as Dr Reddys' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dr Reddys. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA88.4 B92.8 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for RDY Stock Analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.